MRI-guided stereotactic ablative body radiotherapy versus CT-guided percutaneous irreversible electroporation for locally advanced pancreatic cancer (CROSSFIRE): a single-centre, open-label, randomised phase 2 trial

医学 不可逆电穿孔 SABR波动模型 叶黄素 胰腺癌 放射科 人口 放射治疗 中期分析 外科 随机对照试验 癌症 内科学 电穿孔 结直肠癌 奥沙利铂 经济 化学 金融经济学 基因 环境卫生 波动性(金融) 随机波动 生物化学
作者
Florentine E. F. Timmer,Bart Geboers,Alette H. Ruarus,Laurien G. P. H. Vroomen,Evelien A. C. Schouten,Susan van der Lei,Danielle J. W. Vos,Madelon Dijkstra,Hannah H. Schulz,Joyce Bakker,Bente A. T. van den Bemd,M. Petrousjka van den Tol,Robbert S. Puijk,Birgit I. Lissenberg‐Witte,Tanja D. de Gruijl,Jan J.J. de Vries,Frank J. Lagerwaard,Hester J. Scheffer,A. Bruynzeel,Martijn R. Meijerink
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier BV]
卷期号:9 (5): 448-459 被引量:35
标识
DOI:10.1016/s2468-1253(24)00017-7
摘要

Background Pancreatic ductal adenocarcinoma is an aggressive disease with a dismal prognosis. Stage III locally advanced pancreatic cancer is considered unresectable and current palliative chemotherapy regimens only modestly improve survival. Guidelines suggest chemoradiation or stereotactic ablative body radiotherapy (SABR) could be beneficial in certain circumstances. Other local treatments such as irreversible electroporation could enhance patient outcomes by extending survival while preserving quality of life. We aimed to compare the efficacy and safety of MRI-guided SABR versus CT-guided percutaneous irreversible electroporation following standard FOLFIRINOX chemotherapy. Methods CROSSFIRE was an open-label, randomised phase 2 superiority trial conducted at the Amsterdam University Medical Centre (Amsterdam, Netherlands). Eligible patients were aged 18 years or older with confirmed histological and radiological stage III locally advanced pancreatic cancer. The maximum tumour diameter was 5 cm and patients had to be pretreated with three to eight cycles of FOLFIRINOX. Patients were randomly assigned (1:1) to MRI-guided SABR (five fractions of 8 Gy delivered on non-consecutive days) or CT-guided percutaneous irreversible electroporation using a computer-generated variable block randomisation model. The primary endpoint was overall survival from randomisation, assessed in the intention-to-treat population. Safety was assessed in the per-protocol population. A prespecified interim futility analysis was done after inclusion of half the original sample size, with a conditional probability of less than 0·2 resulting in halting of the study. The trial was registered at ClinicalTrials.gov, NCT02791503. Findings Between May 1, 2016, and March 31, 2022, 68 patients were enrolled and randomly assigned to SABR (n=34) or irreversible electroporation (n=34), of whom 64 were treated according to protocol. Of the 68 participants, 36 (53%) were male and 32 (47%) were female, with a median age of 65 years (IQR 57–70). Median overall survival from randomisation was 16·1 months (95% CI 12·1–19·4) in the SABR group versus 12·5 months (10·9–17·0) in the irreversible electroporation group (hazard ratio [HR] 1·39 [95% CI 0·84–2·30]; p=0·21). The conditional probability to demonstrate superiority of either technique was 0·13; patient accrual was therefore stopped early for futility. 20 (63%) of 32 patients in the SABR group versus 19 (59%) of 32 patients in the irreversible electroporation group had adverse events (p=0·8) and five (16%) patients in the SABR group versus eight (25%) in the irreversible electroporation group had grade 3–5 adverse events (p=0·35). The most common grade 3–4 adverse events were cholangitis (two [6%] in the SABR group vs one [3%] in the irreversible electroporation group), abdominal pain (one [3%] vs two [6%]), and pancreatitis (none vs two [6%]). One (3%) patient in the SABR group and one (3%) in the irreversible electroporation group died from a treatment-related adverse event. Interpretation CROSSFIRE did not identify a difference in overall survival or incidence of adverse events between MRI-guided SABR and CT-guided percutaneous irreversible electroporation after FOLFIRINOX. Future studies should further assess the added value of local ablative treatment over chemotherapy alone. Funding Adessium Foundation, AngioDynamics.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
兮云发布了新的文献求助10
1秒前
1秒前
科目三的应助被hyska采纳,获得10
2秒前
1234hai完成签到 ,获得积分10
3秒前
wg发布了新的文献求助10
5秒前
Nole的应助被殷月华采纳,获得10
5秒前
5秒前
风趣忻发布了新的文献求助10
6秒前
xh关注了科研通微信公众号
7秒前
驾驭你的元完成签到,获得积分10
7秒前
7秒前
7秒前
9秒前
jing发布了新的文献求助10
12秒前
可爱的函函的应助被liuliu采纳,获得10
12秒前
慕青的应助被liuliu采纳,获得10
12秒前
12秒前
12秒前
巨小俊发布了新的文献求助10
13秒前
在水一方的应助被Brufo采纳,获得20
14秒前
白华苍松发布了新的文献求助20
14秒前
LeslieWu完成签到,获得积分10
15秒前
15秒前
Nole的应助被喬老師采纳,获得10
16秒前
刘清发布了新的文献求助10
17秒前
17秒前
鸣熠完成签到,获得积分10
18秒前
香蕉觅云的应助被谢富杰采纳,获得10
20秒前
20秒前
可可完成签到 ,获得积分10
20秒前
CipherSage的应助被muderder采纳,获得10
20秒前
21秒前
轻松峻熙发布了新的文献求助10
22秒前
科研通AI6.4的应助被ygy采纳,获得10
22秒前
贾贡献的应助被十二采纳,获得10
22秒前
迟宏珈发布了新的文献求助10
24秒前
文静迎南发布了新的文献求助10
25秒前
25秒前
25秒前
26秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188394
求助须知:如何正确求助?哪些是违规求助? 9576268
关于积分的说明 21846207
捐赠科研通 7786486
什么是DOI,文献DOI怎么找? 3435317
关于科研通互助平台的介绍 2559618
邀请新用户注册赠送积分活动 2482322